Latest Breaking News On - Rupert bartsch - Page 1 : comparemela.com

Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain Metastases

Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

San antonioUnited statesRupert bartschTucatinib tukysaDepartment of medicineUniversity of viennaDivision of oncologyMedical universityAntonio breast cancerMedical university of viennaTuxedo 1 trialTrastuzumab deruxtecanPatients with her2 positive breast cancer active brain metastases

Novel class of drug regresses active brain metastases in breast cancer patients

An Austrian study led by MedUni Vienna showed that active brain metastases in breast cancer patients are partially or even completely regressed by a novel class of drug. This is a chemical conjugate of an antibody and a chemotherapy drug that, according to current findings, opens up a completely new avenue in oncological research and targeted therapy.

Matthias preusserEmily hendersonUniversity hospital viennaDivision of oncology meduni viennaRupert bartsch division of oncologyEuropean medicines agencyDepartment of medicineDivision of oncologyUniversity of viennaMeduni viennaUniversity hospitalRupert bartschHuman epidermal receptorsMedical universityBrain metastasesBreast cancer

ADC shrinks brain metastases in HER2+ breast cancer patients

ADC shrinks brain metastases in HER2+ breast cancer patients
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Rupert bartschMatthias preusserUniversity hospital viennaEuropean medicines agencyDivision of oncologyNature medicineMedical universityMeduni viennaUniversity hospital

Antibody-Drug Conjugate Promising for Breast Cancer With Brain Mets

High intracranial response rates with trastuzumab-deruxtecan observed in TUXEDO-1 trial

United statesComunidad autonoma de catalunaRupert bartschMike bassettMafalda oliveiraHebron university hospitalBreast cancer congressUniversity of viennaMedical universityEuropean societyMedical oncology breast cancer congress